Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.


Related Content

Are Biosimilars The Next Big Opportunity In India?
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)
With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
Bristol-Myers Squibb Plans To Make India Its Global Pharma Innovation Hub


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts